Medication Guide for the perioperative management of oral antineoplastic agents in cancer patients

Author(s):  
Cristina Villanueva-Bueno ◽  
Vicente Escudero-Vilaplana ◽  
Roberto Collado-Borrell ◽  
Álvaro Giménez-Manzorro ◽  
Almudena Ribed ◽  
...  
2015 ◽  
Vol 16 (4) ◽  
pp. 338-343 ◽  
Author(s):  
Shuichi Fukuda ◽  
Kiyokazu Nakajima ◽  
Yasuhiro Miyazaki ◽  
Tsuyoshi Takahashi ◽  
Yukinori Kurokawa ◽  
...  

2019 ◽  
Vol 20 (6) ◽  
pp. 1451 ◽  
Author(s):  
Renata Zajączkowska ◽  
Magdalena Kocot-Kępska ◽  
Wojciech Leppert ◽  
Anna Wrzosek ◽  
Joanna Mika ◽  
...  

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects caused by antineoplastic agents, with a prevalence from 19% to over 85%. Clinically, CIPN is a mostly sensory neuropathy that may be accompanied by motor and autonomic changes of varying intensity and duration. Due to its high prevalence among cancer patients, CIPN constitutes a major problem for both cancer patients and survivors as well as for their health care providers, especially because, at the moment, there is no single effective method of preventing CIPN; moreover, the possibilities of treating this syndrome are very limited. There are six main substance groups that cause damage to peripheral sensory, motor and autonomic neurons, which result in the development of CIPN: platinum-based antineoplastic agents, vinca alkaloids, epothilones (ixabepilone), taxanes, proteasome inhibitors (bortezomib) and immunomodulatory drugs (thalidomide). Among them, the most neurotoxic are platinum-based agents, taxanes, ixabepilone and thalidomide; other less neurotoxic but also commonlyused drugs are bortezomib and vinca alkaloids. This paper reviews the clinical picture of CIPN and the neurotoxicity mechanisms of the most common antineoplastic agents. A better understanding of the risk factors and underlying mechanisms of CIPN is needed to develop effective preventive and therapeutic strategies.


2003 ◽  
Vol 46 (2) ◽  
pp. 101-114 ◽  
Author(s):  
Stuart M. Lichtman ◽  
J.Andrew Skirvin ◽  
Sunitha Vemulapalli

2016 ◽  
Vol 54 (4) ◽  
pp. e17-e32 ◽  
Author(s):  
Tobias Piegeler ◽  
Markus W. Hollmann ◽  
Alain Borgeat ◽  
Philipp Lirk

2020 ◽  
Vol 95 (2) ◽  
pp. 104-113
Author(s):  
Hae-Soo Jeon ◽  
Hee-Kyoo Kim ◽  
Gil-Soon Choi

Background/Aims: Although the number of domestic adverse drug reactions (ADRs) reported in Korea is rapidly increasing, the analysis of ADRs in cancer patients remains limited. We sought to investigate the clinical features of ADRs in cancer patients.Methods: ADR data were collected from a spontaneous reporting system at single university hospital, between July 2010 and June 2015. ADR cases assessed to be “unlikely” or “unclassifiable” as per the criteria of the World Health Organization-Uppsala Monitoring Center were excluded. Additional medical information was retrospectively collected from chart reviews, and clinical features of ADRs were analyzed.Results: In total, 1,455 cases were reported. Of these, 822 ADRs (52.1%) were observed in cancer patients. The mean age of cancer patients was 60.8 years (range, 17–90 years), and 45.9% were male. The most prevalent clinical features were gastrointestinal abnormalities (32.6%), such as nausea and vomiting, followed by skin (28.5%) and neurologic manifestations (26.0%). Fifty-one (6.2%) and 296 cases (36.0%) were classified as severe and moderate, respectively. The most common causative agents were parenteral nutrition (PN) supplements (40.4%), followed by antibiotics (17.8%), analgesics (16.7%), iodinated contrast media (ICM, 10.6%), and vitamins (3.9%). Antineoplastic agents were responsible for 2.9% of cases. PN supplements were commonly associated with severe reactions.Conclusion: Although it is well known that antibiotics, ICM, and analgesics induce ADRs, PN supplements, vitamins, and antineoplastic agents should also be considered as common causes of ADRs in cancer patients. Further investigation and monitoring to determine the causality associated with these agents is required.


Sign in / Sign up

Export Citation Format

Share Document